CENTURY CITY, CA , Jan. 05, 2018 (GLOBE NEWSWIRE) -- HypGen Inc. (OTCQB: HPGN), announced it will present during the Biotech Showcase™ 2018, in San Francisco. HypGen is developing the drug RP-323 for the treatment of Parkinson's disease.
HypGen’s CEO, Dr. McCoy L. Moretz, will present at the “Asia Drug Development Networking Event” hosted by CMIC Holdings and CORCEPT 190 on Sunday, January 7, 2018.
A copy of the presentation is available via the Company’s website at www.hypgeninc.com under the Investor’s Section; or by following this link: Download our CMIC Presentation.
About Dr. McCoy L. Moretz
Dr. McCoy L. Moretz is a Board certified surgeon with more than 30 years of experience, and has operated successful private practices in Atlanta, Georgia and California. Board Certified by the ABO, a member of the American Board of Medical Specialties, Fellow of the American College of Surgeons; American Board of Otolaryngology/Head & Neck Surgery; American Academy of Facial Plastic & Reconstructive surgery; American Academy of Cosmetic Surgery; and American Academy of Otolaryngology / Head & Neck Surgery.
About HypGen Inc.
HypGen intends to focus its efforts on developing therapeutics treatment for Parkinson's disease. HypGen has been assigned all of the right, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016 (the "Patent Application"), titled "COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON'S DISEASE" and all related intellectual property, inventions and trade secrets, data, and clinical study results. More than 10 million people worldwide are impacted by this disease and the market is estimated at $10 billion.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking statements". HypGen may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, HypGen's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the success, timing and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's product candidates, if approved; and other factors, including general economic conditions and regulatory developments, not within the Company's control including sufficient capital to undertake operations, studies and advancements. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. A further list and description of the Company's risks, uncertainties and other factors may be found HypGen's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or www.hypgeninc.com. The forward-looking statements are made only as of the date of this press release and HypGen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.